Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma (Englisch)

In: Liver Cancer ;  8 ,  3 ;  155-171 ;  2018

Wie erhalte ich diesen Titel?

Download
Kommerziell Vergütung an den Verlag: 24,00 € Grundgebühr: 4,00 € Gesamtpreis: 28,00 €
Akademisch Vergütung an den Verlag: 10,00 € Grundgebühr: 2,00 € Gesamtpreis: 12,00 €

Background: Anti-programmed cell death-1(anti-PD1) treatment has shown promising antitumor efficacy in patients with advanced hepatocellular carcinoma (HCC). This study sought to explore the functional significance of programmed death ligand-1 (PD-L1) expression in tumor cells in the tumor microenvironment. Methods: The mouse liver cancer cell line BNL-MEA was transfected with PD-L1 plasmids and stable clones expressing PD-L1 were selected. An orthotopic HCC model was generated by implanting the cells into the subcapsular space of BALB/c mice. Cell growth features were measured by proliferation assay, colony formation, flow cytometry (in vitro), ultrasonography, and animal survival (in vivo). The changes in T-cell function were examined by cytokine assay, expression of T-cell related genes, and flow cytometry. The efficacy of anti-PD1 therapy was compared between the parental and PD-L1-expressing tumors. Results: PD-L1 expression did not affect growth characteristics of BNL-MEA cells but downregulated the expression of genes related to T-cell activation in the tumor microenvironment. Co-culture of PD-L1-expressing BNL-MEA cells with CD8+ T cells reduced T-cell proliferation and expression of cytokines IFNγ and TNFα. Tumors with PD-L1 expression showed better response to anti-PD1 therapy and depletion of CD8+ T cells abolished the antitumor effect. The difference in treatment response between parental and PD-L1-expressing tumors disappeared when a combination of anti-PD1 and sorafenib was given. Conclusions: PD-L1 expression in HCC cells may inhibit T-cell function in the liver tumor microenvironment. Anti-PD1 therapy appeared more effective in PD-L1-expressing than nonexpressing tumors, but the difference was diminished by the addition of sorafenib.

Inhaltsverzeichnis – Band 8, Ausgabe 3

Zeige alle Jahrgänge und Ausgaben

Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Nachweisen der enthaltenen Aufsätze. Die Anzeige der Jahrgänge kann aufgrund fehlender Aufsatznachweise unvollständig oder lückenhaft sein, obwohl die Zeitschrift komplett in der TIB verfügbar ist.

143
Pembrolizumab for the Treatment of Hepatocellular Carcinoma
Kudo, Masatoshi | 2019
155
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
Ou, Da-Liang / Lin, Yu-Yang / Hsu, Chia-Lang / Lin, Yin-Yao / Chen, Chia-Wei / Yu, Jhang-Sian / Miaw, Shi-Chuen / Hsu, Ping-Ning / Cheng, Ann-Lii / Hsu, Chiun | 2018
172
Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results
N’Kontchou, Gisele / Nault, Jean-Charles / Sutter, Olivier / Bourcier, Valerie / Coderc, Emmanuelle / Grando, Veronique / Nahon, Pierre / Ganne-Carrié, Nathalie / Diallo, Abou / Sellier, Nicolas et al. | 2018
186
Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study
Chien, Shih-Chieh / Chen, Chiung-Yu / Cheng, Pin-Nan / Liu, Yi-Shan / Cheng, Hsiu-Chi  / Chuang, Chiao-Hsiung / Chang, Ting-Tsung / Chiu, Hong-Chi / Lin, Yih-Jyh / Chiu, Yen-Cheng | 2018
203
Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma
Scheiner, Bernhard / Kirstein, Martha / Popp, Sabine / Hucke, Florian / Bota, Simona / Rohr-Udilova, Nataliya / Reiberger, Thomas / Müller, Christian / Trauner, Michael / Peck-Radosavljevic, Markus et al. | 2018
218
APPLE News
| 2019
219
The APPLE Association President's Message
| 2019
220
APPLE 2019
| 2019

Ähnliche Titel